Benoit Tessoulin

Nantes, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 106 publications

Outcomes of refractory and early-relapsed large B-cell lymphoma patients after first-line treatment in the prospective Real-world dAta in LYmphoma patients and Survival in Adults (REALYSA) cohort in the pre-CAR T era.

Outcomes of refractory and early-relapsed large B-cell lymphoma patients after first-line treatment in the prospective Real-world dAta in LYmphoma patients and Survival in Adults (REALYSA) cohort in the pre-CAR T era.

Journal: British journal of haematology

Published: May 05, 2026

Brentuximab vedotin as consolidation treatment in patients with stage I/II Hodgkin's lymphoma and FDG-PET positivity after 2 cycles of ABVD: final analysis of the BRAPP2 trial.

Brentuximab vedotin as consolidation treatment in patients with stage I/II Hodgkin's lymphoma and FDG-PET positivity after 2 cycles of ABVD: final analysis of the BRAPP2 trial.

Journal: Haematologica

Published: May 04, 2026

Longitudinal gut microbiome dynamics are associated with clinical outcome and toxicity during ibrutinib therapy.

Longitudinal gut microbiome dynamics are associated with clinical outcome and toxicity during ibrutinib therapy.

Journal: Gut microbes

Published: April 19, 2026

Standardized FDG-PET interpretation during CAR T-cell therapy in R/R DLBCL: a DESCAR-T study.

Standardized FDG-PET interpretation during CAR T-cell therapy in R/R DLBCL: a DESCAR-T study.

Journal: European journal of nuclear medicine and molecular imaging

Published: March 25, 2026

Odronextamab in people with relapsed or refractory follicular lymphoma: plain language summary of the ELM-2 study.

Odronextamab in people with relapsed or refractory follicular lymphoma: plain language summary of the ELM-2 study.

Journal: Future oncology (London, England)

Published: March 02, 2026

Outcomes and salvage strategies for large B-cell lymphoma progressing after second-line CAR T-cell therapy: A DESCAR-T study from the LYSA group.

Outcomes and salvage strategies for large B-cell lymphoma progressing after second-line CAR T-cell therapy: A DESCAR-T study from the LYSA group.

Journal: HemaSphere

Published: December 05, 2025

Large B-cell lymphoma: The LYSA pragmatic guidelines.

Large B-cell lymphoma: The LYSA pragmatic guidelines.

Journal: European journal of cancer (Oxford, England : 1990)

Published: October 21, 2025

CD40/PI3K/FOXO1 axis rewiring drives microenvironment-dependent BIM silencing to sustain lymphoma growth and survival.

CD40/PI3K/FOXO1 axis rewiring drives microenvironment-dependent BIM silencing to sustain lymphoma growth and survival.

Journal: Leukemia

Published: September 18, 2025

Acalabrutinib plus bendamustine and rituximab for older patients with untreated mantle cell lymphoma

Acalabrutinib plus bendamustine and rituximab for older patients with untreated mantle cell lymphoma

Journal: Bulletin du cancer

Published: September 17, 2025

Preemptive Immunoglobulin Prophylaxis Reduces Infections in Patients Treated With Anti-BCMA Bispecific Antibodies.

Preemptive Immunoglobulin Prophylaxis Reduces Infections in Patients Treated With Anti-BCMA Bispecific Antibodies.

Journal: Clinical lymphoma, myeloma & leukemia

Published: September 12, 2025

Response to "high-flow nasal cannula and intubation risk in severe PjP: methodological and clinical perspectives".

Response to "high-flow nasal cannula and intubation risk in severe PjP: methodological and clinical perspectives".

Journal: Annals of intensive care

Published: September 09, 2025

Return to employment outcomes in patients with multiple myeloma.

Return to employment outcomes in patients with multiple myeloma.

Journal: British journal of haematology

Published: August 26, 2025

Showing 1-12 of 106

Last Updated: 09/26/2026